Pfizer ends sale of hormone therapy cream Premarin in Canada

Résumé détaillé

Pfizer will no longer sell its hormone replacement therapy Premarin in Canada following an internal review. The product has been available as a vaginal cream and three strengths…

Pfizer will no longer sell its hormone replacement therapy Premarin in Canada following an internal review. The product has been available as a vaginal cream and three strengths of oral tablets.

Premarin vaginal cream, which is used to treat symptoms of menopause, is currently unavailable and will not be returning, CBC News has confirmed.

According to Pfizer Canada’s pharmaceutical customer service centre, the company will no longer be marketing Premarin vaginal cream and Premarin tablets, although the tablets are expected to remain available through mid-2027.

Pfizer Canada told Reuters that there's been a shortage of the vaginal cream in Canada since June.

Demand for hormone replacement therapy has been rising, particularly in the United States, where prescriptions have increased following the U.S. Food and Drug Association's November 2025 removal of long-standing safety warnings from the treatments.

Some other hormone therapy products to treat menopause symptoms are also facing supply constraints in Canada. Earlier this month, Health Canada said certain strengths of estradiol transdermal patches made by Bayer and Sandoz Canada were in short supply, with intermittent shortages expected to continue until early 2027.

The discontinuation of Premarin products, alongside shortages of some estradiol patches, could add to pressure on Canada's menopause drug supply.

The decision was not related to any new safety, efficacy or quality concerns, Pfizer told Reuters, adding that other treatment options were available in Canada.

Existing inventories of Premarin tablets in 0.3 milligram, 0.625 mg and 1.25 mg strengths are expected to last until about mid-2027, although stocks could run out sooner if demand increases, the company said.

Début de l'article, extrait de CBC News. Pour lire la suite, ouvrez l'article chez le média.